Peritoneal papillary mesothelioma in situ: BAP1 mutation with indolent behavior for 15 years
Authors:
- 10 July 2023
- journal article
- research article
- Published by Springer Nature in Virchows Archiv
- Vol. 483 (6) , 873-878
Abstract
Papillary mesothelioma in situ (PMIS) is a rare and enigmatic disease. Most instances manifest as lesions of the peritoneal serosa. The pathogenesis and behavior of peritoneal PMIS are still poorly understood, and separation from benign well differentiated peritoneal mesothelial tumors (WDPMT) may be challenging. We describe the 15-year long course of a PMIS in an adult male in which inactivating mutations of BAP1, encoding BRCA1 associated protein 1 (BAP1), were identified. Tumor samples were obtained on 2 occasions more than 8y apart. In both samples, the tumor cells were bland, with occasional focal infiltration into the stalks of larger papillary lesions. However, no invasion into subserosal adipose tissue was identified. In both samples the tumor cells did not express nuclear BAP1. Comprehensive genomic analysis of the initial tumor sample revealed a somatic inactivating mutation in BAP1 (predicted effect, Y223*) and a somatic variant of IRS2 (A701_V702insAA). An additional inactivating mutation in BAP1 (predicted effect, T69fs*5) was detected in the later sample. The patient did not receive any treatment and is still alive 15 years after initial presentation. Our experience supports the view that peritoneal PMIS may follow an indolent course for many years and prompts the question whether these tumors should uniformly be treated aggressively.Keywords
This publication has 13 references indexed in Scilit:
- Well-Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from Malignant MesotheliomaCancers, 2020
- Malignant mesothelioma in situ: morphologic features and clinical outcomeLaboratory Investigation, 2020
- Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesotheliomaGenome Medicine, 2019
- Well-differentiated papillary mesothelioma: A 17-year single institution experience with a series of 75 casesAnnals of Diagnostic Pathology, 2019
- Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42Laboratory Investigation, 2019
- BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesotheliomaHuman Pathology, 2018
- Malignant mesothelioma in situHistopathology, 2018
- Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant MesotheliomaAmerican Journal of Surgical Pathology, 2018
- Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3XLaboratory Investigation, 2016
- Well-differentiated Papillary Mesothelioma With Invasive FociAmerican Journal of Surgical Pathology, 2014